Emerging therapeutic treatments based on the production of proteins by delivering mRNA have become increasingly important in recent times. While lipid nanoparticles (LNPs) are approved vehicles for small interfering RNA delivery, there are still challenges to use this formulation for mRNA delivery. LNPs are typically a mixture of a cationic lipid, distearoylphosphatidylcholine (DSPC), cholesterol, and a PEG-lipid. The structural characterization of mRNA-containing LNPs (mRNA-LNPs) is crucial for a full understanding of the way in which they function, but this information alone is not enough to predict their fate upon entering the bloodstream. The biodistribution and cellular uptake of LNPs are affected by their surface composition as well a...
With three FDA-approved products, lipid nanoparticles (LNPs) are under intensive development for del...
High density lipoproteins (HDL) are athero-protective particles under investigation as potential the...
Lipid Nanoparticles (LNPs) are an attractive way of delivering of short interfering RNA (siRNA) for ...
Emerging therapeutic treatments based on the production of proteins by delivering mRNA have become i...
The development of safe and efficacious gene vectors has limited greatly the potential for therapeut...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
The nano-scale dynamics of lipid nanoparticles (LNPs) for drug delivery play a large role in their f...
Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (si...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
RNA-based therapies have shown promise in a wide range of applications, from cancer therapy, treatme...
Atherosclerosis is the main killer in the western world. Today's clinical markers include the total ...
With three FDA-approved products, lipid nanoparticles (LNPs) are under intensive development for del...
High density lipoproteins (HDL) are athero-protective particles under investigation as potential the...
Lipid Nanoparticles (LNPs) are an attractive way of delivering of short interfering RNA (siRNA) for ...
Emerging therapeutic treatments based on the production of proteins by delivering mRNA have become i...
The development of safe and efficacious gene vectors has limited greatly the potential for therapeut...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
The nano-scale dynamics of lipid nanoparticles (LNPs) for drug delivery play a large role in their f...
Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (si...
Apolipoprotein E (ApoE), an important mediator of lipid transportation in plasma and the nervous sys...
RNA-based therapies have shown promise in a wide range of applications, from cancer therapy, treatme...
Atherosclerosis is the main killer in the western world. Today's clinical markers include the total ...
With three FDA-approved products, lipid nanoparticles (LNPs) are under intensive development for del...
High density lipoproteins (HDL) are athero-protective particles under investigation as potential the...
Lipid Nanoparticles (LNPs) are an attractive way of delivering of short interfering RNA (siRNA) for ...